About Lotus Innovative Health

Founded in 2010, Lotus Innovative Health is a start-up biopharmaceutical company specializing in the discovery and development of therapeutics for eye diseases.

We have been studying and researching in the Angiogenesis field for over 20 years and are focused on developing our novel anti-angiogenic drugs for the treatment of west age-related macular degeneration and diabetic retinopathy, both neovascular-based diseases causing vision loss. Lotus Innovative Health has secured research space in Hayward, CA and will be opening a new office and laboratory space for product research & development.


Our mission is to develop and commercialize therapeutics to help elleviate or treat vision loss due to eye disease utilizing our patented anti-angiogenic compounds.


Innovative, Creative & Dynamic (ICD)

ICD is our core value. Being innovative, creative and dynamic is what we want. We strive to find new and exciting ways to utilize our wealth of knowledge and experience in combination with cutting edge technologies and research to enable us to discover and develop therapies for vision loss.

Corporate Team

   Ming-Chung Wong, M.B.A.

Founder and CEO

Ming Wong is the Chief Executive Officer at Lotus Innovative Health, Ltd. from its inception.  Mr. Wong was previously the Co-founder and Chief Operations Officer of Angiogen, Inc. from 1999 to 2006.  While at Security Global Investments, Mr. Wong specialized in pharmaceutical and life science research for a US$1.2B fund.  Mr. Wong was a graduate student in Dr. Tony Hunter’s laboratory at the Salk Institute for Biological Studies, studying the effects of the PTEN tumor suppressor gene on cell cycle regulation.

Mr. Wong holds a B.S. in Molecular Biology and Biochemistry from California State University, Fresno and a M.B.A. in Finance from the Chinese University of Hong Kong.


   Kin-Ping Wong, Ph.D.

Chief Scientific Officer

Dr. Wong is the Dean Emeritus and Professor of the College of Science and Mathematics at California State University, Fresno and an Adjunct Professor of Medicine and Biochemistry and Biophysics at the University of California, San Francisco. His current research focuses on the discovery and development of novel anti-angiogenic therapeutics targeting the vascular network for the treatment of neovascular-based diseases such as cancer and age-related macular degenerations (AMD).

In addition to having been the Founder, Chairman and CEO of RiboGene, Inc. in Dublin, California, Dr. Wong has held positions as Program Director in Biophysics at the National Science Foundation in Washington, D.C., as well as Managing Director and CEO of the Hong Kong Institute of Biotechnology in Hong Kong.  Dr. Wong has served on a number of boards for research institutes and has consulted for governments, biotechnology companies and venture capital firms. He has published over 60 peer-reviewed articles in the scientific literature and is a named inventor on 7 granted and several pending patents.

Dr. Wong received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. from Purdue University.


   W. Andrew Maxwell, Ph.D., M.D.

Vice President for Clinical Affairs

Dr. Maxwell is a nationally renowned eye surgeon and has contributed significantly to the education, research and development of new techniques and understanding of diseases of the eye.

Dr. Maxwell received his Ph.D. in Microbiology and conducted research in anti-microbial drugs at the Stanford Research Institute in Palo Alto, CA. He received his M.D. from the University of California, Los Angeles School of Medicine and completed his ophthalmology fellowship at the Jules Stein Eye institute at UCLA. Dr. Maxwell served as a Clinical Consultant and Scientific Advisor to Alcon Laboratories and is currently with the Eye Institute of St. Agnes Hospital in Fresno, California.